Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

JVCKENWOOD launches joint research with Oxford University and Sysmex R&D Center Europe GmbH to establish a system for predicting the onset of Pre-eclampsia using exosomes.

Copyright: Shutterstock (3d illustration of cells secreting exosomes)


JVCKENWOOD Corporation (JVCKENWOOD) announces the launch of joint research with Oxford University*1 (UK) and Sysmex R&D Center Europe GmbH*2, an overseas subsidiary of Sysmex Corporation, aiming to establish a system for predicting the onset of preeclampsia using exosomes*3.

Dr Manu Vatish, Senior Clinical Fellow at the Nuffield Department of Women's and Reproductive Health has been awarded a grant from Sysmex-JVCKENWOOD for his project:  “To optimise the combination of antibody and assay method for exocounter to predict the onset of preeclampsia in first-trimester pregnancy". He commented:


manu"We are very excited to be working in partnership with Sysmex-JVCKENWOOD . This project is at the cutting edge of exosome research and we are confident that it will yield data that will ultimately have real clinical value".





Preeclampsia, a hypertensive disease of pregnancy, presents with various clinical symptoms and signs—mainly high blood pressure and proteinuria after 20 weeks of pregnancy. When it becomes severe, it causes eclampsia (convulsive seizures), restricted fetal development, and premature delivery. About 5% of pregnant women worldwide develop this disease, threatening the lives of both mother and child, but there is currently no effective treatment other than delivering the pregnancy (irrespective of gestational age). On the other hand, it has been known that taking a preventive drug from the beginning of pregnancy (before the onset of symptoms) may reduce the incidence of the disease, so a test for predicting onset is needed to appropriately prescribe the preventive drug.



The joint research aims to establish a technology for predicting the onset of preeclampsia using exosomes, and combines findings from long-term research activities by Oxford University and a diagnostic technologies using exosomes, which has jointly been being developed by JVCKENWOOD and Sysmex Corporation since 2016.

Oxford University has discovered that vesicle particles released by the placenta into the body called exosomes are effective for the early prediction of the onset of preeclampsia. The number of exosomes unique to pregnant women who have developed the disease is measured with our ExoCounter, a high-precision exosomes measurement system, and, combined with the technologies and knowledge in in vitro diagnostics field that Sysmex R&D Center Europe possesses, we will promote our joint research to establish a system for predicting the onset of the disease.


*1: Nuffield Department of Women's & Reproductive Health, University of Oxford.

*2: An overseas subsidiary of Sysmex Corporation, established in Hamburg, Germany, in October 2018. In addition to exploring medical needs and technologies in Europe, developing new clinical applications, pre-marketing assessments of products, and building networks with medical and research institutes, the company works actively to acquire local R&D personnel and opportunities for new collaborations with local companies.

*3: About 50 to 100 nm vesicle particles secreted from many types of cell present in body fluids such as blood, saliva, and urine


Similar stories

Dawes-Redman Education awarded funds from Huntleigh Healthcare

The Dawes-Redman Education programme which offers virtual CTG Analysis training sessions to Obstetric consultants, antenatal and student midwifes has received generous funds from Huntleigh Healthcare for the next 3 years.

First UK pilot study of newborn screening for spinal muscular atrophy (SMA) launched in Oxford

Spinal muscular atrophy (SMA) is a rare, but treatable, genetic disease affecting approximately 1 in 10,000 births, and it typically presents in infancy and early childhood.

Professor Collins awarded Sir Jules Thorn Translational Biomedical Research Award 2021

Professor Sally Collins has been awarded the prestigious and highly competitive Sir Jules Thorn Translational Biomedical Research Award 2021 for further translational development of the OxNNet Toolkit.

Global INTERCOVID-2022 Study launched to compare Covid-19 during pregnancy, with pregnant women without the infection.

The Oxford Maternal & Perinatal Health Institute (OMPHI) has launched the 2022 round of the global study to evaluate the effects of Covid-19 variants and vaccination in pregnancy.

Success with the Pfizer Maternal C-19 Vaccine Trial

Congratulations to Prof. Manu Vatish and the OSPREA-Gynae team on recruiting their first participant to the Pfizer maternal C-19 vaccine trial on 22nd July.

How do unborn babies and mothers communicate via the placenta?

DPhil student Neva Kandzija wins an Oxford Sparks competition to have her Placenta research transformed into a two minute animation film for free.